Table 4.

Breast cancer ORs (95% CIs) for the MTHFR C677T and A1298C polymorphisms and HRT use at baseline

GenotypeNever
Past
Current*
nOR (95% CI)nOR (95% CI)nOR (95% CI)
677
    CC240/6191.00103/2211.00181/2951.00
    CT170/4181.00 (0.78-1.28)81/1501.06 (0.72-1.58)187/2820.95 (0.72-1.26)
    TT63/1371.07 (0.75-1.54)27/501.07 (0.60-1.92)37/740.62 (0.39-0.98)
    P0.770.760.09
1298
    AA294/7301.00141/2741.00250/3841.00
    AC148/3830.99 (0.78-1.26)59/1290.88 (0.60-1.29)124/2350.74 (0.56-0.99)
    CC31/611.23 (0.77-1.96)11/181.21 (0.53-2.75)31/321.28 (0.74-2.21)
    P0.610.850.46
  • NOTE: Adjusted for age at blood draw and race and/or ethnicity.

  • * Current: Current use of hormonal replacement therapy at baseline (100 cases and 168 controls were excluded due to missing information on HRT use).

  • No. cases/no. controls.

  • P value for a gene dosage term assigned 1, 2, and 3 for 0, 1, and 2 variant alleles, respectively.